作者
David A Cooper, Roy T Steigbigel, Jose M Gatell, Jurgen K Rockstroh, Christine Katlama, Patrick Yeni, Adriano Lazzarin, Bonaventura Clotet, Princy N Kumar, Joseph E Eron, Mauro Schechter, Martin Markowitz, Mona R Loutfy, Jeffrey L Lennox, Jing Zhao, Joshua Chen, Desmond M Ryan, Rand R Rhodes, John A Killar, Lucinda R Gilde, Kim M Strohmaier, Anne R Meibohm, Michael D Miller, Daria J Hazuda, Michael L Nessly, Mark J DiNubile, Robin D Isaacs, Hedy Teppler, Bach-Yen Nguyen
发表日期
2008/7/24
期刊
New England Journal of Medicine
卷号
359
期号
4
页码范围
355-365
出版商
Massachusetts Medical Society
简介
Background
We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) with triple-class drug resistance and in whom antiretroviral therapy had failed.
Methods
We conducted subgroup analyses of the data from week 48 in both studies according to baseline prognostic factors. Genotyping of the integrase gene was performed in raltegravir recipients who had virologic failure.
Results
Virologic responses to raltegravir were consistently superior to responses to placebo, regardless of the baseline values of HIV-1 RNA level; CD4 cell count; genotypic or phenotypic sensitivity score; use or nonuse of darunavir, enfuvirtide, or both in optimized background therapy; or demographic characteristics. Among patients in the two studies combined who were using both enfuvirtide and darunavir for …
引用总数
学术搜索中的文章
DA Cooper, RT Steigbigel, JM Gatell, JK Rockstroh… - New England Journal of Medicine, 2008